Evidence map›Paper›PMID 37380925›Full record

SynthesisHeart failure reviews2023

Sacubitril/valsartan and arrhythmic burden in patients with heart failure and reduced ejection fraction: a systematic review and meta-analysis.

A Pozzi, R Abete, E Tavano, S L Kristensen, F Rea, A Iorio, A Iacovoni, G Corrado, C Wong

Abstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Heart failure reviews, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 3 countries.

A PozziCardiology Department, Valduce Hospital, Como, Italy. andreawellsvabg@gmail.com.ORCID 0000-0002-9819-2148
R AbeteCardiology Department, Papa Giovanni XXIII Hospital, Bergamo, Italy.
E TavanoOspedale di Circolo Busto Arsizio, Busto Arsizio, Italy.
S L KristensenCardiology Department, Rigshospitalet University Hospital, Copenhagen, Denmark.
F ReaDepartment of Statistics and Quantitative Methods, University of Milano-Bicocca, Milan, Italy.
A IorioCardiology Department, Papa Giovanni XXIII Hospital, Bergamo, Italy.
A IacovoniCardiology Department, Papa Giovanni XXIII Hospital, Bergamo, Italy.
G CorradoCardiology Department, Valduce Hospital, Como, Italy.
C WongCardiology Department, Southmead Hospital, Bristol, UK.
Ospedale Papa Giovanni XXIII · ITOspedale Valduce · ITOspedale di Circolo di Busto Arsizio · ITRigshospitalet · DKSouthmead Hospital · GBUniversity of Milano-Bicocca · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this study was to assess whether angiotensin receptor/neprilysin inhibitor (ARNI) decreases ventricular arrhythmic burden compared to angiotensin-converting enzyme inhibitors or angiotensin receptor antagonist (ACE-I/ARB) treatment in chronic heart failure with reduced ejection fraction (HFrEF) patients. Further, we assessed if ARNI influenced the percentage of biventricular pacing. A systematic review of studies (both RCTs and observational studies) including HFrEF patients and those receiving ARNI after ACE-I/ARB treatment was conducted using Medline and Embase up to February 2023. Initial search found 617 articles. After duplicate removal and text check, 1 RCT and 3 non-RCTs with a total of 8837 patients were included in the final analysis. ARNI was associated with a significative reduction of ventricular arrhythmias both in RCT (RR 0.78 (95% CI 0.63-0.96); p = 0.02) and observational studies (RR 0.62; 95% CI 0.53-0.72; p < 0.001). Furthermore, in non-RCTs, ARNI also reduced sustained (RR 0.36 (95% CI 0.2-0.63); p < 0.001), non-sustained VT (RR 0.67 (95% CI 0.57-0.80; p = 0.007), ICD shock (RR 0.24 (95% CI 0.12-0.48; p < 0.001), and increased biventricular pacing (2.96% (95% CI 2.25-3.67), p < 0.001). In patients with chronic HFrEF, switching from ACE-I/ARB to ARNI treatment was associated with a consistent reduction of ventricular arrhythmic burden. This association could be related to a direct pharmacological effect of ARNI on cardiac remodeling.Trial registration: CRD42021257977.

Indexed as

AminobutyratesArrhythmias, CardiacBiphenyl CompoundsHeart FailureStroke VolumeValsartanAngiotensin Receptor AntagonistsDrug CombinationsHumansAminobutyratesAngiotensin Receptor AntagonistsBiphenyl CompoundsDrug Combinationssacubitril and valsartan sodium hydrate drug combinationValsartanAngiotensin receptor/neprilysin inhibitorArrhythmiasHeart failureICD shockSacubitril/valsartanVentricular tachycardia

Identifiers

PMID37380925
OpenAlexW4382501492

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.